CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Several studies have demonstrated that shock therapy is an effective treatment for improving depression symptoms. Shock therapy, medically known as electroconvulsive therapy (ECT), is a treatment ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Postpartum depression affects many new mothers, increasing suicide risk. New research shows preventive cognitive behavioral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Over the last 20 years, we’ve seen major strides in the treatment options for major depressive disorder. We now understand that depression isn’t the same for everyone. The idea is to identify ...